Domestic pharma units relieved as Trump’s price cut policy lacks teeth
US president Donald Trump's drug pricing proposal, while weaker than expected, has given a breather to the domestic pharma industry. The executive order lacks details on punitive actions against violating pharma manufacturers, but emphasizes on ending price discrimination against US patients.